Oncogenic NRAS and KRAS mutations are prevalent in human juvenile and chronic myelomonocytic leukemia (JMML/CMML). However, additional genetic mutations cooperating with oncogenic RAS in JMML/ CMML progression and/or their transformation to acute myeloid leukemia (AML) remain largely unknown. Here we tested the potential genetic interaction of DNMT3A mutations and oncogenic RAS mutations in leukemogenesis. We found that Dnmt3a −/− induces multiple hematopoietic phenotypes after a prolonged latency, including T-cell expansion in the peripheral blood, stress erythropoiesis in the spleen and myeloid malignancies in the liver. Dnmt3a −/− significantly promoted JMML/CMML progression and shortened the survival of Kras G12D/+ mice in a cellautonomous manner. Similarly, downregulating Dnmt3a also promoted myeloid malignancies in Nras G12D/+ mice. Further studies show that Dnmt3a deficiency rescues Kras G12D/+ -mediated depletion of hematopoietic stem cells and increases self-renewal of Kras G12D/+ myeloid progenitors (MPs). Moreover,~33% of animals developed an AML-like disease, which is driven by Kras G12D/+ ; Dnmt3a −/− MPs. Consistent with our result, COSMIC database mining demonstrates that the combination of oncogenic RAS and DNMT3A mutations exclusively occurred in patients with JMML, CMML or AML. Our results suggest that DNMT3A mutations and oncogenic RAS cooperate to regulate hematopoietic stem and progenitor cells and promote myeloid malignancies.
INTRODUCTION
Constitutively active mutations in NRAS and KRAS genes are identified in human hematopoietic malignancies at significant frequencies. 1 In particular, oncogenic NRAS and KRAS mutations are predominant in juvenile myelomonocytic leukemia (JMML), myeloproliferative variant of chronic myelomonocytic leukemia (MP-CMML) and the M4 and M5 monocytic subtypes of acute myeloid leukemia (AML) (including both de novo AML and secondary AML with antecedent JMML/CMML). Consistently, mice expressing endogenous oncogenic Kras or Nras develop highly penetrant JMML/MP-CMML-like phenotypes. [2] [3] [4] [5] [6] [7] [8] Although these animals rarely develop AML spontaneously, acquisition of other mutations does promote their malignant transformation to monocytic AML. 7 These findings indicate that JMML, MP-CMML and M4/M5 AML are related malignancies in which oncogenic Ras signaling has an essential role.
Although genetic mutations in a few genes are reported to be concurrent with oncogenic RAS mutations 9 in myeloid malignancies, their functional significances remain largely unknown. Acquisition of two copies of oncogenic RAS alleles, including NRAS G12D/G12D and KRAS G13D/G13D , is associated with JMML/CMML progression in human and mouse (COSMIC database and Wang et al., 6 Dunbar et al., 10 Kohlmann et al., 11 Kato et al. 12 ). Consistently, Nras G12D/G12D mice develop JMML/MP-CMML phenotypes much more rapidly than Nras G12D/+ mice, 8 indicating that incremental activation of Ras signaling is a pathological mechanism contributing to JMML/CMML development. In contrast, knocking down Tet2 expression in Nras G12D/+ bone marrow cells does not seem to promote JMML/CMML progression or its malignant transformation. 13 These data suggest that the potential genetic interaction between oncogenic RAS and other concurrent mutations have to be validated in vivo on a case-by-case basis.
Recent work focusing on AML with a normal karyotype identified mutations in DNA methyltransferase 3A (DNMT3A) with biological, clinical and potential therapeutic relevance in AML and other types of myeloid malignancies. 9, 14 Approximately 90% of DNMT3A mutations occur as a single copy mutation over wild-type DNMT3A. 15 Although the predominant mutation at the codon R882 has been shown to be a dominant-negative mutation, 16, 17 loss of Dnmt3a in the mouse hematopoietic system does not induce leukemogenesis up to 6 months of age. 18 In contrast, recipients transplanted with Dnmt3a-deficient hematopoietic stem cells (HSCs) developed both myeloid and lymphoid malignancies. 19 Furthermore, loss of Dnmt3a promotes lung tumor progression in oncogenic Kras mice. 20 Consistent with this finding, a group of AML patients were identified who carried both oncogenic RAS and DNMT3A mutations. 9, 21 However, it remains unclear whether these two mutations cooperate in myeloid leukemia development.
Here we show that loss of Dnmt3a promotes multiple hematopoietic defects after a prolonged latency, which are distinct from recipients transplanted with Dnmt3a −/− HSCs. Downregulation of Dnmt3a (deleting a single copy or both copies) in oncogenic Ras models not only significantly promote JMML/MP-CMML progression but also leads to transformation to acute myeloid diseases in a cell-autonomous manner. Our finding is consistent with COSMIC database mining results showing that oncogenic RAS and DNMT3A mutations were only concurrent in myeloid malignancies, including JMML, CMML and AML. Further mechanistic studies demonstrate that Dnmt3a deficiency promotes myeloid diseases in oncogenic Kras model through rescuing Kras G12D/+ -mediated depletion of HSCs and increasing self-renewal of Kras G12D/+ myeloid progenitor (MP) cells. These mutant MPs could initiate myeloid malignancies in recipients and thus serve as leukemia-initiating cells. Our results suggest that changes in epigenetic landscapes and signaling networks co-regulate hematopoietic stem and progenitor cells to promote myeloid leukemias.
MATERIALS AND METHODS Mice
All mouse lines were maintained in a pure C57BL/6 genetic background (4N10). Dnmt3a conditional knockout mice (Dnmt3a fl/fl (Nguyen et al. 22 ); provided by Dr Qiang Chang) were crossed to mice bearing a conditional oncogenic Kras (Kras Lox-stop-Lox (LSL) G12D/+ ) or Mx1-Cre mice to generate mice carrying both alleles (Kras LSL G12D/+ ; Dnmt3a fl/+ and Dnmt3a fl/+ ; Mx1-Cre, respectively). Kras LSL G12D/+ ; Dnmt3a fl/+ mice were further crossed to Dnmt3a fl/+ ; Mx1-Cre mice to generate our experimental mice, including Kras LSL G12D/+ ; Dnmt3a fl/fl ; Mx1-Cre, Kras LSL G12D/+ ; Mx1-Cre, Dnmt3a fl/fl ; Mx1-Cre and Mx1-Cre mice. CD45.1-positive congenic C57BL/6 recipient mice were purchased from National Cancer Institute (NCI, Bethesda, MD, USA). Cre expression was induced through intraperitoneal injection of 2.5 μg/g body weight (GE Healthcare, Pittsburgh, PA, USA) of polyinosinicpolycytidylic acid (pI-pC) every other day for two times. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by an Animal Care and Use Committee at UW-Madison. The program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Flow cytometric analysis of hematopoietic tissues
For lineage analysis of the peripheral blood, bone marrow and spleen, flow cytometric analyses were performed as previously described. 4 MPs in the bone marrow and spleen were analyzed as previously described. 8 HSCs in the bone marrow and spleen were analyzed as described in Kong et al. 23 Because hind limb bone marrow represents~25% of the total bone marrow, the number of HSCs in total bone marrow is calculated as 4 × the number of HSCs in hind limb bone marrow. The stained cells were analyzed on a FACS Calibur (BD Biosciences, San Jose, CA, USA) or a MACSQuant Analyzer (Miltenyi Biotec Inc., Cambridge, MA, USA). Antibodies specific for the following surface antigens were purchased from eBioscience (San Diego, CA, USA): CD45.2 (104), B220 (RA3-6B2), CD19 (eBio1D3), Thy1.2 (53-2.1), Mac-1 (M1/70), Gr-1 (RB6-8C5), CD4 (GK1.5), CD8 (53-6.7), CD3 (145-2C11), IgM (II/41), IL7Rα (A7R34), Sca-1 (D7), TER119 (TER-119), CD34 (RAM34), and c-Kit (2B8). FcγRII/III (2.4G2) was purchased from BD Biosciences. CD150 (TC15-12F12.2) was purchased from Biolegend (San Diego, CA, USA).
Additional methods are described in Supplementary Methods.
RESULTS
Somatic deletion of Dnmt3a promotes acute myeloid diseases in Kras G12D/+ mice To determine whether Dnmt3a has an important role in Kras G12D/ + -mediated hematopoietic malignancies, we generated Dnmt3a fl/fl ; Mx1-Cre, Kras LSL G12D/+ ; Mx1-Cre and Kras LSL G12D/+ ; Dnmt3a fl/fl ; Mx1-Cre mice. Administration of pI-pC in these compound mice stimulates endogenous interferon production and thus induces Cre expression from the interferon-α/β-inducible Mx1 promoter, which in turn leads to the expression of oncogenic Kras from its endogenous locus and/or somatic deletion of Dnmt3a. 24 We refer to these pI-pC-treated compound mice as Dnmt3a −/− , Kras G12D/+ and Kras G12D/+ ; Dnmt3a −/− mice, respectively, and pI-pC-treated Mx1-Cre or wild-type mice as control mice throughout this paper.
Somatic deletion of Dnmt3a significantly enhanced leukemia phenotypes and shortened the lifespan of Kras G12D/+ mice ( Figure 1 ). Two days after the second pI-pC injection, control, Dnmt3a −/− , Kras G12D/+ and Kras G12D/+ ; Dnmt3a −/− mice were killed and assessed for hematopoietic phenotypes (Figures 1b-d ). Consistent with previous reports, [2] [3] [4] [5] Kras G12D/+ mice developed an acute myeloproliferative neoplasm (MPN), closely resembling human JMML/MP-CMML. This disease was manifested by splenomegaly ( Figure 1b ) with significant extramedullary hematopoiesis ( Figure 1d ), expanded monocyte and neutrophil compartments in various hematopoietic tissues (Figure 1c ), elevated white blood cell counts in the peripheral blood and defective erythroid and megakaryocyte development ( Supplementary Table S1 ). Loss of Dnmt3a not only significantly enhanced the MPN phenotypes in Kras G12D/+ mice (Figures 1b and c and Supplementary Table S1 ) but also promoted the development of AML-like phenotypes in about one-third of the animals, as demonstrated by accumulation of immature myeloblast cells in the spleen (Figure 1d ).
Dnmt3a deficiency induces multiple hematopoietic defects
Although all Dnmt3a −/− mice survived in an overtly healthy condition for 6 months,~14% of Dnmt3a fl/fl ; Mx1-Cre mice without pI-pC treatment died with multiple hematopoietic defects within 13 months owing to the leaky expression of Cre over time (Figure 2a ). In these moribund mice, the fraction of T cells in the peripheral blood was significantly elevated but the thymus size and structure were essentially normal, indicating a chronic T-cell expansion ( Figure 2b ). Our result is consistent with a recent report that Dnmt3a prevents malignant mouse lymphopoiesis. 25 In the enlarged spleen (~4-5-fold over control spleens), the normal architecture was completely effaced by extramedullary hematopoietic tissue that was dominated by erythroid and megakaryocytic elements with fewer numbers of maturing myeloid cells. Sheets of blasts were not evident. Consistent with the hematoxylin and eosin sections, flow cytometric analysis of splenocytes also demonstrated the dominance of erythroid lineage cells, suggesting a stressed erythropoiesis ( Figure 2c ). The markedly enlarged livers (~10-15-fold over control livers) were dramatically altered with only small islands of hepatocytes present separated by sheets of discohesive cells. Based on the histological evaluation, this is most consistent with a histiocytic or myeloid sarcoma ( Figure 2d ).
To validate our result, we set up another cohort of Dnmt3a fl/fl ; Mx1-Cre mice injected with pI-pC and monitored them closely. They consistently displayed a transient anemia 2 months after pI-pC injections with significantly lower red blood cell count, hemoglobin and hematocrit (Supplementary Figure S1A ). However, the other aspects of hematopoiesis were indistinguishable from those of control mice (Supplementary Figure S1B ). Further analysis of erythropoiesis in bone marrow and spleen showed that the red pulp in the Dnmt3a −/− spleen was moderately enlarged (Supplementary Figure S2A ). Consistent with this result, flow cytometric analysis using CD71 and TER119 demonstrated that the erythroid compartment in the Dnmt3a − / − spleen was moderately but significantly expanded with increased Region II cells and decreased Region IV cells (Supplementary Figure S2B and S2D). In vitro colony assay revealed that the number of CFU-E (colony forming unit-erythroid) progenitors in the Dnmt3a − / − spleen was significantly increased (Supplementary Figure S2E ) without detectable change of their sensitivity to erythropoietin stimulation (Supplementary Figure S2F) . These results suggest that loss of Dnmt3a affects erythroid differentiation, which can be compensated by stress erythropoiesis in the spleen. Compared with Dnmt3a fl/fl ; Mx1-Cre mice without pI-pC treatment, Dnmt3a −/− mice succumbed to similar hematopoietic defects (including T-cell expansion in the peripheral blood, stress erythropoiesis in the spleen and myeloid malignancies in the liver) with a much higher penetrance (Figure 2a) .
To investigate the cell-autonomous role of Dnmt3a deficiency in leukemogenesis, we transplanted 2.5 × 10 5 Dnmt3a − / − bone marrow cells along with same number of competitor cells into individual lethally irradiated mice (Supplementary Figure S3 ). To our surprise, only 2 out of the 23 recipients died of hematopoietic maliganacies 300 days after transplantation (Supplementary Figure S3A ). The first one was found dead with enlarged thymus and spleen, while the second one was killed at the moribund stage and also showed enlarged spleen and thymus (Supplementary Figure S3B ). Detailed flow cytometric analysis of the second mouse revealed a lethal acute T-cell lymphoblastic leukemia/lymphoma (T-ALL) throughout the entire hematopoietic system (Supplementary Figure S3C ). Together, our results suggest that somatic downregulation of Dnmt3a does promote leukemogenesis as a first genetic hit.
Downregulation of Dnmt3a promotes myeloid diseases in
Nras G12D/+ mice Approximately 90% of DNMT3A mutations in human leukemia patients occur as a single copy mutation over wild-type DNMT3A. 15 Although the predominant mutation at the codon R882 has been shown to be a dominant-negative mutation, 16, 17 other mutations have not been characterized in detail. We investigated whether loss of a single copy of Dnmt3a would promote oncogenic Ras-induced leukemogenesis. As was seen in oncogenic Kras-induced non-small cell lung carcinoma, 20 we did not observe significant acceleration or enhancement of MPN development in Kras G12D/+ ; Dnmt3a +/ − mice compared with Kras G12D/+ mice (our unpublished data). This could be due to the strong MPN phenotypes in Kras G12D/+ mice. Therefore, we generated Nras G12D/+ ; Dnmt3a fl/+ ; Mx1-Cre mice to address this question (referred as Nras G12D/+ ; Dnmt3a +/ − mice after pI-pC treatment). Compared with Nras G12D/+ mice, Nras G12D/+ ; Dnmt3a +/ − mice indeed showed significantly shortened lifespan and developed more severe MPN phenotypes (Figures 3a and c) . As with Kras G12D/+ ; Dnmt3a −/− mice, about one-third of Nras G12D/+ ; Dnmt3a +/ − mice developed AML-like phenotypes (Figure 3b ). Thus our data indicate that downregulating Dnmt3a and oncogenic Nras cooperate to promote myeloid diseases in vivo. Loss of Dnmt3a rescues Kras G12D/+ -mediated HSC depletion and increases self-renewal of Kras G12D/+ MPs To study the mechanisms of how Dnmt3a deficiency promotes myeloid diseases in oncogenic Kras mice, we first examined the HSC compartment because mutant HSCs serve as JMML/MP-CMML-initiating cells in these animals. 4, 26 HSCs are defined as Lin − CD41 − CD48 − c-Kit + Sca-1 + CD150 + cells throughout the paper (Figure 4a ). Although the frequency of Dnmt3a −/− HSCs was moderately increased in bone marrow compared with that of control HSCs, the absolute number was comparable in the whole body (total bone marrow+spleen) ( Figure 4b ). Consistent with previous reports, 5, 26 the HSC number in Kras G12D/+ mice was significantly less than that in control mice, indicating an oncogenic Kras-mediated HSC depletion. In contrast, the HSC compartment in Kras G12D/+ ; Dnmt3a −/− mice was comparable to that in control mice, suggesting that depletion of Kras G12D/+ HSCs was rescued by loss of Dnmt3a. The total number of multipotent progenitors (defined as Lin − CD41 − CD48 − c-Kit + Sca-1 + CD150 − cells; Figure 4a ) in Kras G12D/+ ; Dnmt3a −/− mice was concomitantly increased compared with that in control and Kras G12D/+ mice (Figure 4c ), whereas the LSK (Lin − Sca-1 + c-Kit + ) compartment was comparable to controls (Figure 4d ).
We then analyzed the MPs in all groups of animals ( Figure 5 ). In Dnmt3a −/− mice, the number of MPs, including common MPs, granulocyte-macrophage progenitors and megakaryocyteerythroid progenitors, was significantly decreased in bone marrow compared with that in control mice (Figures 5a-e ). Consistently, Dnmt3a −/− bone marrow cells formed significantly fewer colonies in semi-solid cultures (Figure 5f capability than Kras G12D/+ or Dnmt3a −/− MPs in the replating assay ( Figure 5g ). Together, our data suggest that loss of Dnmt3a promotes myeloid diseases in Kras G12D/+ mice through rescuing Kras G12D/+ -mediated HSC depletion and enhancing self-renewal of Kras G12D/+ MPs.
Deletion of Dnmt3a promotes myeloid malignancies in Kras G12D/+ mice in a cell-autonomous manner
To determine whether Dnmt3a deficiency has a cell-autonomous role in promoting leukemogenesis in Kras G12D/+ model, we transplanted control, Kras LSL G12D/+ ; Mx1-Cre or Kras LSL G12D/+ ; Dnmt3a fl/fl ; Mx1-Cre bone marrow cells into lethally irradiated mice ( Figure 6 ). Four weeks after transplantation, recipient mice were injected with pI-pC as before. We did not observe significant change of lifespan between recipients with Kras G12D/+ cells and those with Kras G12D/+ ; Dnmt3a −/− cells (Figure 6a ). This could be due to the leaky expression of oncogenic Kras but not efficient Dnmt3a deletion before the pI-pC induction.
Although different groups of donor cells engrafted recipients at a comparable level (Figure 6b ), recipients of Kras G12D/+ ; Dnmt3a −/− cells developed an acute myeloid disease with a much higher incidence than those with Kras G12D/+ cells (60% versus 20%; Figure 6c ). Consistently, the myeloid disease phenotypes characteristic in Kras G12D/+ mice, including splenomegaly and expanded myeloid compartments in various hematopoietic tissues (Figures 6d and e ) as well as defective phenotypes in erythoid and megakaryocytic lineages of cells ( Supplementary Table S2 ), were more prominent in the recipients of Kras G12D/+ ; Dnmt3a −/− cells than those of Kras G12D/+ cells. Similarly to primary nontransplanted mice, about one-third of myeloid diseases that developed in the recipients of Kras G12D/+ ; Dnmt3a −/− cells were AML-like, and the rest of them closely resembled an MPN (Supplementary Figure S4) . In contrast, all the myeloid diseases that developed in the recipients with Kras G12D/+ cells were MPN. Genotyping of myeloid disease cells from recipient bone marrow revealed that WT Kras allele was significantly downregulated in 50-75% of samples ( Supplementary Figure S5) , which might be caused by clonal expansion of leukemia cells with uniparental disomy of the oncogenic Kras allele or deletion of WT Kras allele. In conclusion, our results indicate that loss of Dnmt3a and oncogenic Ras cooperate to promote myeloid malignancies, which is consistent with the identification of activating RTK/RAS pathway mutations in Dnmt3a −/− induced AML in mice. 19, 27 To test the human relevance of our finding, we conducted a COSMIC database search to quantify the incidence of myeloid versus lymphoid malignancies in leukemia patients with oncogenic RAS mutations (Figure 6f ). We found that~50% of patients with an oncogenic KRAS mutation and~70% of patients with an oncogenic NRAS mutation had a myeloid malignancy. Acquisition of additional copies of oncogenic RAS mutations did not significantly change the disease incidence. However, 100% of patients with both oncogenic RAS and DNMT3A mutations had developed myeloid malignancies, including JMML, CMML and AML. This result suggests that oncogenic RAS and DNMT3A mutations intrinsically interact or cooperate to promote leukemogenesis in myeloid cells.
In addition to myeloid neoplasms, all the recipients of Kras G12D/+ ; Dnmt3a −/− cells developed T-ALL (Supplementary Figure S6) . In comparison to the T-ALL that developed in the recipients of Kras G12D/+ cells, approximately 30% of Kras G12D/+ ; Dnmt3a −/− -derived tumors contained a significant percentage of CD4 − CD8 − T cells, suggesting a more immature phenotype. T-ALL developed in both groups of recipients carried Type 1 deletions in the Notch1 locus, which render ligand-independent cleavage of Notch1 and elevated expression of intracellular C-terminus Notch1. Our results suggest that active Notch1 signaling promotes T-ALL development in both genetic contexts. Kras G12D/+ ; Dnmt3a −/− MPs are capable of initiating myeloid malignancies in recipient mice Because Kras G12D/+ ; Dnmt3a −/− bone marrow cells promoted highly penetrant myeloid malignancies in a cell-autonomous manner ( Figure 6 ) and Kras G12D/+ ; Dnmt3a −/− MPs displayed enhanced selfrenewal in vitro (Figure 5f ), we investigated whether these mutant progenitors could initiate myeloid diseases in recipient mice and thus serve as leukemia-initiating cells. Mutant LSK cells and LK Sca-1 − MPs were sorted and transplanted with competitor cells into lethally irradiated recipients ( Table 1 ). All the recipients with mutant LSK cells succumbed to hematopoietic malignancies, one with T-ALL and MPN, one with MPN and one with AML. Six out of the seven recipients with mutant MPs died, and careful analysis of four mice revealed that three died with MPN and one with AML. Our results indicate that some of the Kras G12D/+ ; Dnmt3a −/− MPs are transformed to leukemiainitiating cells.
DISCUSSION
In this paper, we demonstrate that somatic downregulation of Dnmt3a induces leukemogenesis as a first genetic hit. Downregulating Dnmt3a cooperates with oncogenic Ras to promote myeloid malignancies in a cell-autonomous manner in mice, consistent with the genetic findings in human leukemia patients. Furthermore, our data suggest that Dnmt3a deficiency promotes myeloid diseases through regulating the functions of Kras G12D/+ HSCs and MPs (Figure 7) .
Although the predominant mutation at the codon R882 of DNMT3A is a dominant-negative mutation, 16, 17 loss of Dnmt3a in the mouse hematopoietic system does not induce leukemogenesis up to 6 months of age. 18 However, we found that Dnmt3a −/− mice developed multiple hematopoietic defects after a prolonged latency (Figure 2 ). Our results are consistent with human studies reporting that DNMT3A mutations in HSCs lead to clonal hematopoietic expansion and thus act as the first/early genetic event during AML development. [28] [29] [30] [31] Interestingly, the hematopoietic phenotypes developed in Dnmt3a −/− mice (T-cell expansion in the peripheral blood, stress erythropoiesis in the spleen and myeloid malignancies in the liver) are distinct from those in recipients transplanted with Dnmt3a −/− HSCs 19, 27 or total bone marrow cells (Supplementary Figure S3 ), which primarily developed myelodysplastic syndrome/AML and T-ALL. This could be due to both cell-autonomous and cell-nonautonomous effects of Dnmt3a deficiency in non-transplanted Dnmt3a −/− mice. For example, we previously showed that pI-pC injection could sufficiently induce Cre expression in the liver. 6 Noticeably, the survival of our bone marrow transplantation cohort mice is significantly prolonged than those reported. 19, 27 This difference might be due to the lower number of Dnmt3a −/− HSCs we transplanted and the presence of competitor cells.
We found that Dnmt3a deficiency and Kras G12D/+ cooperate to induce myeloid malignancies in a cell-autonomous manner in vivo.
Dnmt3a −/− significantly promoted JMML/CMML progression and shortened the survival of Kras G12D/+ mice (Figure 1 ). Recipients transplanted with Kras G12D/+ ; Dnmt3a −/− bone marrow cells developed JMML/CMML at a much higher incidence than those Figure 6 . Recipients transplanted with Kras G12D/+ ; Dnmt3a −/− cells develop myeloid diseases with a high penetrance. Lethally irradiated mice were transplanted with 2.5 × 10 5 bone marrow cells from different groups of mice along with same number of competitor cells. Four weeks after transplantation, Cre expression was induced by pI-pC injections. (a) Kaplan-Meier survival curves of different groups of recipient mice were plotted against days after transplantation. P-values were determined by the Log-rank test. (b) The percentages of donor-derived cells in different groups of recipients. (c) Disease distribution patterns in recipient mice transplanted with Kras G12D/+ or Kras G12D/+ ; Dnmt3a −/− cells. We define the mice with a myeloid disease when donor-derived monocytes consist 420% of white blood cells in peripheral blood. Chi-square analysis was performed. (d-e) Quantitative analysis of spleen weight (d) and donor-derived monocytes and neutrophils in the bone marrow (BM), spleen (SP) and peripheral blood (PB) (e) from moribund recipient mice. The results are presented as means ± s.d. (f) Human patients with either oncogenic KRAS or NRAS mutations from COSMIC database v67 were divided into three groups: (1) samples with only one copy of KRAS or NRAS mutation, (2) samples with additional RAS mutations, including more than one copy of KRAS or NRAS mutations, or containing mutations in both NRAS and KRAS genes, and (3) samples with concurrent DNMT3A and one copy of KRAS or NRAS mutation. The patients were further stratified based on their disease types, lymphoid or myeloid malignancies. P-values were determined by the Chi-square analysis. *Po 0.05, **Po 0.01 and ***P o0.001.
transplanted with Kras G12D/+ cells ( Figure 6 ). Moreover,~33% of animals developed an AML-like disease. Similarly, loss of one copy of Dnmt3a also promoted myeloid diseases in Nras G12D/+ mice, consistent with the previous study using a retroviral construct to overexpress oncogenic Nras in Dnmt3a −/− bone marrow cells. 19 However, the survival data from our genetic model is very different from that of RasG12D overexpression study, which could be mainly explained by the expression levels of oncogenic Nras (endogenous level versus overexpression). Indeed, although recipients transplanted with Kras G12D/+ or Nras G12D/+ cells do not develop AML spontaneously, 4, 6, 26, 32 recipients with bone marrow cells overexpressing NrasG12D develop a highly penetrant CMML/ AML rapidly. 33 The in vivo genetic interaction between oncogenic Ras and Dnmt3a −/− in myeloid diseases is also supported by the identification of activating RTK/RAS pathway mutations (c-Kit V750M and Kras G12D ) in Dnmt3a −/− -induced AML in mice. 19, 27 We believe that our results are highly relevant to human physiology, because the combination of oncogenic RAS (including both NRAS and KRAS) and DNMT3A mutations exclusively occurred in patients with myeloid leukemias, including JMML, CMML and AML (Figure 6f ).
Our results demonstrate that genetic interaction between Dnmt3a deficiency and Kras G12D/+ regulates the functions of HSCs and MPs to drive myeloid leukemogenesis. We recently showed that stronger oncogenic Ras signaling (fo example, Nras G12D/G12D ) shifts HSC self-renewal to differentiation and leads to HSC exhaustion. 23 Similar mechanisms might be also applicable to Kras G12D/+ HSCs. However, Kras G12D/+ -mediated HSC depletion is antagonized by loss of Dnmt3a, which is likely to contribute to the significantly increased incidence of myeloid malignancies in recipients with Kras G12D/+ ; Dnmt3a −/− cells. Our result is consistent with a previous study reporting that Dnmt3a −/− maintains HSC self-renewal in the presence of oncogenic Ras. 19 We found that expression of endogenous oncogenic Ras (for example, Kras G12D/+ or Nras G12D/+ ) promotes progenitor cell growth in vivo and in vitro, 2, 3, [5] [6] [7] in sharp contrast to the negative effect of RasG12D overexpression on progenitor growth in vitro. 19 This is likely due to the different expression levels of oncogenic Ras used in the studies. Consistent with a previous report, 27 we observed moderately increased self-renewal of Dnmt3a −/− MPs in a re-plating assay. Moreover, Kras G12D/+ and Dnmt3a −/− act synergistically to promote self-renewal in MPs, which are transformed to leukemia-initiating cells and drive AML-like diseases in vivo. Our data provide a strong rationale to target both epigenetic regulators and aberrant cytokine signaling in treating myeloid leukemias. (3) AML (1) Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; LSK, Lin-Sca-1 + c-Kit + ; MP, myeloid progenitor; MPN, myeloproliferative neoplasm; T-ALL, acute T-cell lymphoblastic leukemia/lymphoma. LSK and MP cells were flow sorted from Kras G12D/+ ; Dnmt3a −/− BM and transplanted with congenic competitor cells into lethally irradiated recipients. Mice were monitored closely until a moribund stage. Note: some animals died before we could catch and analyze them. Figure 7 . Schematic illustration summarizes the phenotypes in different genetic groups of animals.
